Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways

Zeng,Chao; Wen,Ming; Liu,Xiaomei

doi:10.3892/ol.2018.8027

Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways

Authors:
- Chao Zeng
- Ming Wen
- Xiaomei Liu
View Affiliations

Affiliations: Department of Orthopedics, Weifang Traditional Chinese Medical Hospital, Weifang, Shandong 261041, P.R. China, Oncology and Hematology Department, Huangdao District People's Hospital, Qingdao, Shandong 266000, P.R. China
Published online on: February 12, 2018 https://doi.org/10.3892/ol.2018.8027
Pages: 6029-6035

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although it is established as a marker of cancer-associated fibroblasts, the expression of fibroblast activation protein (FAP) is not restricted to stromal cells; its expression in multiple types of tumor cell and its pro‑tumor functions have been reported. However, the role of FAP in angiogenesis in osteosarcoma remains uncharacterized. In the present study, it was identified that the mRNA and protein expression levels of FAP and vascular endothelial growth factor‑A (VEGF‑A) corresponded to each other in MG63, U2‑OS and HOS osteosarcoma cells. Subsequent to upregulating FAP in MG63 cells, VEGF‑A mRNA and protein expression significantly increased; subsequent to downregulating FAP in U2‑OS cells, VEGF‑A mRNA and protein expression significantly declined. These changes in VEGF‑A level were also detected in the cell supernatant with ELISA. Conditioned medium (CM) from MG63 cells overexpressing FAP promoted the phosphorylation of AKT and extracellular signal‑regulated kinase (ERK) in human umbilical vein endothelial cells (HUVECs), as well as the proliferation rate. The CM from U2‑OS cells with FAP knockdown inhibited the proliferation rate of HUVECs. The phosphorylation of AKT and ERK was increased in MG63 cells overexpressing FAP, but reduced in U2‑OS cells with FAP knockdown. Furthermore, treatment with the AKT inhibitor LY294002 or the ERK inhibitor U0126 inhibited the upregulation of VEGF‑A induced by FAP expression. Collectively, the results suggest that FAP expression in osteosarcoma cells promotes angiogenesis.

View Figures

View References

1	Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, et al: Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 45:799–803. 2013. View Article : Google Scholar : PubMed/NCBI
2	Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici M, Kusuzaki K and Baldini N: Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget. 5:7575–7588. 2014. View Article : Google Scholar : PubMed/NCBI
3	Lu J, Song G, Tang Q, Zou C, Han F, Zhao Z, Yong B, Yin J, Xu H, Xie X, et al: IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling. J Clin Invest. 125:1839–1856. 2015. View Article : Google Scholar : PubMed/NCBI
4	Garcia A and Singh H: Bevacizumab and ovarian cancer. Ther Adv Med Oncol. 5:133–141. 2013. View Article : Google Scholar : PubMed/NCBI
5	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar : PubMed/NCBI
6	Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV and Backer JM: Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res. 6:42016. View Article : Google Scholar : PubMed/NCBI
7	Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zi FM, He JS, Li Y, Wu C, Wu WJ, Yang Y, Wang LJ, He DH, Yang L, Zhao Y, et al: Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway. Cancer Biol Ther. 15:1413–1422. 2014. View Article : Google Scholar : PubMed/NCBI
9	Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegård J, Stenling R, Oberg A and Palmqvist R: High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol. 34:1013–1020. 2013. View Article : Google Scholar
10	Hua X, Yu L, Huang X, Liao Z and Xian Q: Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn Pathol. 6:1112011. View Article : Google Scholar : PubMed/NCBI
11	Liu R, Li H, Liu L, Yu J and Ren X: Fibroblast activation protein. Cancer Biol Ther. 13:123–129. 2014. View Article : Google Scholar
12	Lai D, Ma L and Wang F: Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells. Int J Oncol. 41:541–550. 2012. View Article : Google Scholar : PubMed/NCBI
13	Mentlein R, Hattermann K, Hemion C, Jungbluth AA and Held-Feindt J: Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors. Biol Chem. 392:199–207. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yuan D, Liu B, Liu K, Zhu G, Dai Z and Xie Y: Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma. J Surg Oncol. 108:157–162. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, et al: VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 34:3107–3119. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H and Imamura M: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 78:1379–1384. 1998. View Article : Google Scholar : PubMed/NCBI
17	Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:9–22. 1999. View Article : Google Scholar : PubMed/NCBI
18	Cross MJ, Dixelius J, Matsumoto T and Claesson-Welsh L: VEGF-receptor signal transduction. Trends Biochem Sci. 28:488–494. 2003. View Article : Google Scholar : PubMed/NCBI
19	Kelly T, Huang Y, Simms AE and Mazur A: Fibrobl Activation Protein-α: A key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol. 297:83–116. 2012. View Article : Google Scholar : PubMed/NCBI
20	Jia J, Martin TA, Ye L and Jiang WG: FAP-α (Fibroblast activation protein-α) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol. 15:162014. View Article : Google Scholar : PubMed/NCBI
21	Shi M, Yu DH, Chen Y, Zhao CY, Zhang J, Liu QH, Ni CR and Zhu MH: Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 18:840–846. 2012. View Article : Google Scholar : PubMed/NCBI
22	Adeoye OO, Bouthors V, Hubbell MC, Williams JM and Pearce WJ: VEGF receptors mediate hypoxic remodeling of adult ovine carotid arteries. J Appl Physiol (1985). 117:777–787. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wu Y, Huang A, Li T, Su X, Ding H, Li H, Qin X, Hou L, Zhao Q, Ge X, et al: MiR-152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17. FEBS Lett. 588:2063–2069. 2014. View Article : Google Scholar : PubMed/NCBI
24	Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
25	Sasore T and Kennedy B: Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo. PLoS One. 9:e1052802014. View Article : Google Scholar : PubMed/NCBI
26	Khan KH, Yap TA, Yan L and Cunningham D: Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer. 32:253–265. 2013. View Article : Google Scholar : PubMed/NCBI
27	Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, Kung HF, Lai L and Jiang BH: miR-21 induced angiogenesis through AKT and ERK Activation and HIF-1α expression. PLoS One. 6:e191392011. View Article : Google Scholar : PubMed/NCBI
28	Wang H, Wu Q, Liu Z, Luo X, Fan Y, Liu Y, Zhang Y, Hua S, Fu Q, Zhao M, et al: Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 5:e11552014. View Article : Google Scholar : PubMed/NCBI